News.

  • Kaleido wins at the Transform Awards Europe 2017!

    ViCentra is delighted to announce that Kaleido – our hotly-anticipated new insulin delivery system – was awarded Bronze in the category ‘Best visual identity from the healthcare and pharmaceutical sector’ at last week’s eighth annual Transform Awards Europe. Established in 2009, the Transform Awards recognise excellence in brand development, rebranding and the journey’s brands make, and […]

  • ViCentra announces new Chairman of the Board

    Leading late-stage startup ViCentra, a company focused on the development, manufacture and commercialisation of Kaleido, the insulin pump designed to help people with diabetes live life on their own terms, has today announced the appointment of Jan Keltjens to the role of Chairman of its Board of Directors. In addition to his new role, Mr. […]

  • ViCentra appoints two new medical and scientific advisors

    ViCentra, manufacturer of the Kaleido insulin delivery system, today announced the appointment of Dr. David Kerr and Dr. Fred Storms as medical and scientific advisors to its team. Drs. Kerr and Storms are both internationally recognised experts in the treatment of diabetes mellitus, and bring a wealth of expertise and knowledge of healthcare provision and […]

  • Remmert Laan joins ViCentra’s Board

    ViCentra today announced that Remmert Laan, President of specialist diabetes consultancy, Diabetes Insights, LLC, has joined the ViCentra Board as a Non-executive Board Member. Prior to launching Diabetes Insights, LLC in 2015, Rem held the position of Executive Director of the William Sansum Diabetes Center in California. He has more than 15 years’ experience in […]

  • ViCentra Board announce change in management

    In anticipation of the imminent commercialisation of the Kaleido insulin delivery system, the ViCentra Board are announcing today a change in management that prepares the Company for the next phase in its future. Joseph Cefai stepped down as CEO on April 1st 2016. Joseph will take up the role of Special Advisor to the Board […]

  • LSP leads financing round in ViCentra

    LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of ViCentra B.V., a private Dutch company commercializing the Kaleido insulin pump system for diabetes patients.  The syndicate, led by LSP with participation from existing investor INKEF will invest EUR 10 million. The funding will support […]